SIP DELEGATION MEETS WITH MARTIN SEYCHELL, Deputy Director General, DG SANTE
On the 12th of January, a delegation of SIP - Joop van Griensven (PAE), Patrice Forget (European Pain Federation, EFIC), Bianca Ferraiolo (ACN) and Norbert van Rooij (Grunenthal) - met with Martin Seychell, Deputy Director-General for Health in the European Commission and Stefan Schreck (Head of Unit -Health Programme and Chronic Disease Unit) in order to discuss SIP’s policy recommendations and to understand how the Commission could help pursue these.
Read more here.
SIP 2017 Registration Opens
We are pleased to announce that the registration portal for the SIP Symposium taking place in Malta on the 7th-9th of June 2017 is now available online. This event will take place under the auspices of the 2017 Maltese Presidency of the Council of the EU.
The Working Group topics to be discussed are:
European and national platforms addressing the societal impact of pain
Pain and employment
Pain as a quality indicator for health systems
Existing challenges, models and best practices in pain policy
Pain, disease, symptom or a disabling health state
Find out more about the registration, including the agenda, here.
The Innovative Medicines Initiative (IMI) adds pain to its agenda
November 2016 - The Innovative Medicines Initiative (IMI) has published the following topics under consideration for inclusion in IMI2 - Call 10, scheduled for launch in December 2016: For more information, please click here.
The Societal Impact of Pain (SIP)
- a Multi-Stakeholder Platform in Europe
The "Societal Impact of Pain" (SIP) is an international platform created in 2010 as a joint initiative of EFIC and the pharmaceutical Grünenthal GmbH and aims for
- raising awareness of the relevance of the impact that pain has on our societies, health and economic systems
- exchanging information and sharing best-practices across all member states of the European Union
- developing and fostering European-wide policy strategies & activities for an improved pain care in Europe (Pain Policy).
The platform provides opportunities for discussion for health care professionals, pain advocacy groups, politicians, insurances, representatives of health authorities, regulators and budget holders.
The scientific framework of SIP is under the responsibility of the European Pain Federation EFIC®. The pharmaceutical company Grünenthal GmbH is responsible for funding and non-financial support (e.g. logistical support). The scientific aims of the SIP symposia have been endorsed by a large number of international and national pain advocacy groups, scientific organisations and authorities. (About SIP)